SRDX News and Press, Surmodics Inc. From 11/01/19

Surmodics, Inc. (SRDX) Q4 2019 Earnings Conference Call October 31, 2019 05:00 PM ET Company Participants Tim Arens - Vice President of Finance & Chief Financial Officer Gary Maharaj - President & Chief Executive Officer Conference Call Participants Brooks O'Neil - La...

Gainers:  Rexahn Pharmaceuticals (NASDAQ: REXN ) +45% . California Resources Corporation (NYSE: CRC ) +40% . BeiGene (NASDAQ: BGNE ) +34% . El Pollo Loco Holdings (NASDAQ: LOCO ) +28% . Acorda Therapeutics (NASDAQ: ACOR ) +26% . American Axle & Manufacturing Holdings (NYSE: A...

Image source: The Motley Fool. SurModics   (NASDAQ: SRDX) Q4 2019 Earnings Call Oct 31, 2019 , 5:00 p.m. ET Operator Continue reading

Surmodics (NASDAQ: SRDX ): Q4 Non-GAAP EPS of $0.37 in-line; GAAP EPS of $0.26 beats by $0.01 . More news on: Surmodics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 fourth quarter ended September 30, 2019, and provided its financial outlook for fiscal 2020. Summary of Fourth...

Surmodics (NASDAQ: SRDX ) received a boost on Tuesday (October 29) when the US Food and Drug Administration (FDA) granted the company breakthrough device status for its Sundance sirolimus-coated balloon (SCB) catheter. The Sundance SCB catheter — which has been designated to improve...

Sundance™ Sirolimus-Coated Balloon will receive prioritization throughout the FDA submission and review process to provide patients and physicians timely access to medical devices Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technol...

Webcast is Live at 4 p.m. (CT) Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter fiscal 2019 conference call on Thursday, October...

Surmodics (NASDAQ: SRDX ) has completed the enrollment of 446 subjects in its TRANSCEND study comparing its SurVeil drug-coated balloon (DCB) to Medtronic's (NYSE: MDT ) IN.PACT Admiral DCB in patients with peripheral artery disease. More news on: Surmodics, Inc., Medtronic plc, Abbott...

Study designed to evaluate safety, efficacy of the company’s next-generation SurVeil™ drug-coated balloon Company Raises 2019 Revenue and EPS Guidance Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the heal...